Theriva BiologicsTOVX
About: Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Employees: 22
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
3.4% more ownership
Funds ownership: 4.62% [Q1] → 8.02% (+3.4%) [Q2]
8% less funds holding
Funds holding: 24 [Q1] → 22 (-2) [Q2]
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
76% less capital invested
Capital invested by funds: $1.37M [Q1] → $328K (-$1.04M) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for TOVX.
Financial journalist opinion
Based on 3 articles about TOVX published over the past 30 days